Kai Knopp
Overview
Explore the profile of Kai Knopp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalies K, Knopp K, Koch S, Pilowski C, Wurmbrand L, Sedding D
PLoS One
. 2025 Feb;
20(2):e0319381.
PMID: 40019880
Senescent endothelial cells (EC) are key players in the pathophysiology of cardiovascular diseases and are characterized by a reduced angiogenic and regenerative potential. Therefore, targeting these cells has been suggested...
2.
Dutzmann J, Kefalianakis Z, Kahles F, Daniel J, Gufler H, Wohlgemuth W, et al.
Circ Heart Fail
. 2024 May;
17(5):e010936.
PMID: 38695175
Background: Intermittent fasting has shown positive effects on numerous cardiovascular risk factors. The INTERFAST-MI trial (Intermittent Fasting in Myocardial Infarction) has been designed to study the effects of intermittent fasting...
3.
Kalies K, Knopp K, Wurmbrand L, Korte L, Dutzmann J, Pilowski C, et al.
Sci Rep
. 2024 Feb;
14(1):4271.
PMID: 38383692
Circulating endothelial cells (CEC) are arising as biomarkers for vascular diseases. However, whether they can be utilized as markers of endothelial cell (EC) senescence in vivo remains unknown. Here, we...
4.
Dutzmann J, Bode L, Kalies K, Korte L, Knopp K, Kloss F, et al.
Front Cardiovasc Med
. 2022 Aug;
9:956041.
PMID: 36017090
Background: Empagliflozin, an inhibitor of the sodium glucose co-transporter 2 (SGLT2) and developed as an anti-diabetic agent exerts additional beneficial effects on heart failure outcomes. However, the effect of empagliflozin...
5.
Dutzmann J, Knopp K, Kefalianakis Z, Daniel J, Gufler H, Wohlgemuth W, et al.
BMJ Open
. 2022 Apr;
12(4):e050067.
PMID: 35393305
Introduction: Preclinical studies consistently show robust disease-modifying effects of intermittent fasting in animal models of cardiovascular disease. However, the impact of intermittent fasting on cardiovascular endpoints after myocardial infarction has...
6.
Dutzmann J, Haertle M, Daniel J, Kloss F, Musmann R, Kalies K, et al.
Cardiovasc Res
. 2020 May;
117(3):850-862.
PMID: 32353113
Aims: Recent studies revealed that the bromodomain and extra-terminal (BET) epigenetic reader proteins resemble key regulators in the underlying pathophysiology of cancer, diabetes, or cardiovascular disease. However, whether they also...
7.
Fu H, Alabdullah M, Grossmann J, Spieler F, Abdosh R, Lutz V, et al.
Cell Death Dis
. 2019 Nov;
10(12):880.
PMID: 31754207
Monocytes and macrophages contribute to pathogenesis of various inflammatory diseases, including auto-inflammatory diseases, cancer, sepsis, or atherosclerosis. They do so by production of cytokines, the central regulators of inflammation. Isoprenylation...
8.
Stieger P, Daniel J, Tholen C, Dutzmann J, Knopp K, Gunduz D, et al.
J Am Heart Assoc
. 2017 Jun;
6(6).
PMID: 28637776
Background: Following myocardial infarction (MI), peri-infarct myocardial edema formation further impairs cardiac function. Extracellular RNA (eRNA) released from injured cells strongly increases vascular permeability. This study aimed to assess the...